IRIS
DUMINUCO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 275
NA - Nord America 206
AF - Africa 106
AS - Asia 16
OC - Oceania 3
Totale 606
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 201
IT - Italia 193
CI - Costa d'Avorio 82
IE - Irlanda 51
SN - Senegal 20
BE - Belgio 8
UA - Ucraina 8
CN - Cina 7
FR - Francia 5
NG - Nigeria 4
SG - Singapore 4
AU - Australia 3
CA - Canada 3
FI - Finlandia 3
GB - Regno Unito 3
DE - Germania 2
HK - Hong Kong 2
IN - India 2
MX - Messico 2
CH - Svizzera 1
SI - Slovenia 1
TR - Turchia 1
Totale 606
Salva come PNG Salva come JPEG
Città #
Abidjan 82
Ashburn 52
Dublin 49
Chandler 43
Rome 25
Catania 21
Dakar 20
Milan 17
Brussels 8
Los Angeles 7
Cambridge 6
Lawrence 6
Turin 6
Washington 6
Piazzola Sul Brenta 5
Abuja 4
Boardman 4
Misterbianco 4
Paris 4
Lamezia Terme 3
Lappeenranta 3
Melbourne 3
Naples 3
Palermo 3
Piacenza 3
Santa Venerina 3
Aci Sant'Antonio 2
Andover 2
Cernusco sul Naviglio 2
Florence 2
Hong Kong 2
Lonigo 2
Melilli 2
Messina 2
Orvieto 2
Pedara 2
Seattle 2
Singapore 2
Trecastagni 2
Veracruz 2
Aci Castello 1
Augusta 1
Barcellona Pozzo di Gotto 1
Bremen 1
Cosenza 1
Des Moines 1
Easton 1
Floridia 1
Fort St. James 1
Frankfurt am Main 1
Gioiosa Marea 1
Gosport 1
Hyderabad 1
Islington 1
Kherson 1
Lentini 1
Ljubljana 1
Mascalucia 1
Paternò 1
Perpignan 1
Pune 1
Rosolini 1
Wilmington 1
Woodbridge 1
Zurich 1
Totale 443
Salva come PNG Salva come JPEG
Nome #
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 56
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 42
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 39
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 35
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 33
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 32
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 31
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 30
VEXAS-like syndrome: a potential new entity? 28
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 27
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 25
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 25
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study 21
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes 21
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 20
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 19
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 18
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association 18
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 15
A case of high-risk AML in a patient with advanced systemic mastocytosis 14
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review 13
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 13
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors 12
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 12
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 9
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 8
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 6
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases 5
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 4
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 3
Myelofibrosis: In Search for BETter Targeted Therapies 3
Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma 2
Totale 639
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.875
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 0 0 6 4 3 1 6 14 5 13
2022/2023230 7 15 5 12 12 20 7 43 51 14 34 10
2023/2024357 26 60 22 55 13 88 33 36 6 17 1 0
Totale 639